# Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

> **NCT01302405** · PHASE1 · TERMINATED · sponsor: **Prism Pharma Co., Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** PRI-724

## Key facts

- **NCT ID:** NCT01302405
- **Lead sponsor:** Prism Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2015-01
- **Final completion:** 2015-06
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** closing due to low enrollment, no safety issues
- **Last updated:** 2017-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302405, "Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01302405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*